National Academies Committee to Review Advances Made to the IRIS Process¹ DELS-BEST-17-03 Feb 1-2, 2018

We are pleased that the National Academies is reviewing the progress made by the EPA Integrated Risk Information System (IRIS).² The IRIS program identifies and characterizes the potential human health impacts of chemicals and determines "acceptable" levels of exposure to a chemical or substance. IRIS assessments provide hazard characterizations and dose-response assessments for cancer and non-cancer outcomes. While IRIS assessments are not regulations, they are used by regulators – at the EPA, by local, state and regional governments, and around the world – to set health-based standards for chemicals in air, water, food or soil.

IRIS assessments are also used to inform non-regulatory initiatives pursued by forward-thinking and sustainable chemical and product manufacturers, fabricators, and retailers. For example, reliable, transparent, credible scientific IRIS chemical assessments are relied upon by members the American Sustainable Business Council (ASBC), which represents over 250,000 businesses, local and state chambers of commerce, and investors. In comments to the National Academies during its 2014 review of the IRIS program, ASBC pointed out that, "A safer marketplace helps to dispel consumer fears, spurs innovation, decreases legal liability, and increases shareholder value." ³

The 2014 National Academies Committee review was very supportive of the IRIS program's successes in addressing previous NAS process concerns: "Overall, Review of EPA's Integrated Risk Information System Process finds that substantial improvements in the IRIS process have been made, and it is clear that EPA has embraced and is acting on the recommendations in the NRC formaldehyde report. The recommendations of this report should be seen as building on the progress that EPA has already made."⁴

It should be noted that no committee of the National Academies has ever disagreed with the scientific conclusions of IRIS assessments, but only the adequacy of the process and presentation of information.

Since the 2014 NAS review, the IRIS program has made significant continued progress towards implementing a systematic review process consistent with national and global efforts, including the systematic review developed by EPA's sister agency, the NIEHS National Toxicology Program, Office of Health Assessment and Translation (OHAT) and the Navigational Guide (NavGuide), a method developed by academic experts. Both the OHAT and NavGuide systematic review methods are designed to effectively address the full range of data relevant to environmental health assessments (e.g., human, animal, and in vitro/mechanistic studies), and include tools to assess potential bias of studies.

¹ More information at: https://www8.nationalacademies.org/cp/projectview.aspx?key=49904

² http://dels.nas.edu/Upcoming-Workshop/Review-Advances-Made/AUTO-2-82-78-I

³ ASBC comments to National Academies Joint Meeting: Committee to Review the Formaldehyde Assessment in the NTP 12th RoC and the Committee to Review the Styrene Assessment in the NTP 12th RoC, March 2013. Available here: https://www.nrdc.org/sites/default/files/hea_13032002a.pdf

⁴ National Research Council. 2014. Review of EPA's Integrated Risk Information System (IRIS) Process. Washington, DC: The National Academies Press. https://doi.org/10.17226/18764

More recently, a review of the IRIS program generated praise from EPA's own Science Advisory Board (SAB): "The program has fully adopted the principles of systematic review, and incorporated automation and publicly available software platforms to modernize the process...it is now standard practice for the [IRIS] program to engage stakeholders in an early scoping and problem formulation phase, thereby allowing stakeholders to provide important input at the very beginning of the process."⁵

While we support the progress of the IRIS program, and urge this Committee to do the same, we have two concerns: (1) the politicization of the IRIS program by shifting it from the office of science and research programs to the office of toxics programs; (2) the potential for over-confidence and therefore inappropriate use of data from alternative test methods. Our concerns are discussed below, for the Committee's consideration.

(1) We are concerned that EPA may shift the IRIS program out of the Office of Research and Development (ORD) and into the Office of Chemical Safety and Pollution Prevention (OCSPP) which regulates pesticides and toxic chemicals. This shift would move it from a science and research office to a regulatory policy office under the management of Nancy Beck, a chemical industry lobbyist prior to her recent political appointment at EPA. The chemical industry's opposition to the IRIS program is well-documented and long-standing.⁶ Dr. Beck's previous foray into developing risk assessment guidelines was a failure, as evidenced by the NAS conclusion that the draft government-wide risk assessment bulletin which she authored while at the Office of Management and Budget (OMB) was "fundamentally flawed" and the unprecedented recommendation for its withdrawal (NAS 2007).⁷

We are concerned that EPA may assimilate the IRIS program within the TSCA program, as directed in the Senate FY2018 Appropriations Bill (see Minority response).⁸ We are opposed to this move as it would narrow IRIS's potential scope and thwart its purpose. The TSCA Program is focused on developing risk evaluations (risk assessments) of industrial chemicals to comply with the requirements of that one law. The IRIS program, however, is intended to function more broadly (and independently) to produce information on chemicals to be used for a variety of purposes and actions pursuant to numerous statutes and other federal, state and local bodies. Policy makers and the public would be robbed of the benefits of the IRIS program if it simply subsumed into the risk assessment process for implementing TSCA.

⁷ Available at http://www8.nationalacademies.org/onpinews/newsitem.aspx?RecordID=11811

⁵ Science Advisory Board comments on EPA's response to recommendations on the Integrated Risk Information System. September 1, 2017. EPA-SAB-17-008. Available at:

https://yosemite.epa.gov/sab/SABPRODUCT.NSF/RSSRecentAdditionsBOARD/A9A9ACCE42B6AA0E8525818E004C C597/\$File/EPA-SAB-17-008.pdf

⁶ The Chemical Industry Delay Game: How the Chemical Industry Ducks Regulations of the Most Toxic Substances. Jennifer Sass and Daniel Rosenberg. NRDC report. 2011. Available at https://www.nrdc.org/resources/chemical-industry-delay-game

⁸ November 2017 Senate Approps Bill for FY2018. Available at https://www.appropriations.senate.gov/imo/media/doc/FY2018-INT-CHAIRMEN-MARK-BILL.PDF

See Minority response here: https://www.appropriations.senate.gov/news/minority/summary-fy2018-interiorenvironment-appropriations-chairmans-mark-released

Furthermore, the OCSPP is now developing TSCA review methods that are contrary to those recommended by the NAS in its previous review of the IRIS program (NAS 2014).⁹ We are particularly concerned about the potential under TSCA to adopt a policy of favoring industry-sponsored studies by establishing a preference for guideline studies and for studies conducted using Good Laboratory Practice (GLP) standards. Such a preference has long been promoted by chemical industry scientists and consultants.¹⁰ The US Food and Drug Administration (FDA) first issued GLP standards in 1978 after a criminal investigation into chemical testing labs found evidence of widespread fraud and misconduct.¹¹ EPA's GLP rules for chemical regulatory tests followed shortly thereafter. While GLP requirements have been helpful in ensuring that commercial labs retain better records and not commit rampant fraud, they are not an accurate measure of study quality per se. The 2014 NAS IRIS review report pointed out the limitations of GLP standards, including that they fail to prevent flawed, unreliable or biased-by-design studies.¹² Simply put, GLP should not be relied upon to support public health decisions and placing the IRIS program under the direction of EPA's toxics office makes such an approach more likely.¹³

(2) As noted above, we are also concerned about IRIS (and other EPA assessment programs) moving toward inappropriate or premature use of information from alternative test methods (ATMs) to dismiss or disregard potentially hazardous chemicals or endpoints (false negatives). While the potential exists for alternative test methods to be used to identify toxicity and exposure potential, there are several limitations that demonstrate the need for additional research and development and avoid the potential for false negatives:¹⁴

Lack of metabolic capacity – The inability of current ATMs, like those used in the ToxCast[™] platform, to mimic the metabolic capacity within humans (and across species) means that relying solely on ATMs could result in EPA failing to identify toxicity that would otherwise occur in an intact living system (e.g., a human body).

Becker RA, Janus ER, White RD, Kruszewski FH, Brackett RE. Good Laboratory Practices and Safety Assessments. Environmental Health Perspectives. 2009;117(11):A482-A483. doi:10.1289/ehp.0900884.

¹¹ Markowitz GE, Rosner D. Deceit and Denial: The Deadly Politics of Industrial Revolution. Berkeley, CA: University of California Press; 2002.

¹² NAS 2014 IRIS report. Pages 62-63. Available at: https://doi.org/10.17226/18764.

¹³ Myers JP, vom Saal FS, Akingbemi BT, Arizono K, Belcher S, Colborn T, Chahoud I, Crain DA, Farabollini F, Guillette LJ Jr, Hassold T, Ho SM, Hunt PA, Iguchi T, Jobling S, Kanno J, Laufer H, Marcus M, McLachlan JA, Nadal A, Oehlmann J, Olea N, Palanza P, Parmigiani S, Rubin BS, Schoenfelder G, Sonnenschein C, Soto AM, Talsness CE, Taylor JA, Vandenberg LN, Vandenbergh JG, Vogel S, Watson CS, Welshons WV, Zoeller RT. Why public health agencies cannot depend on good laboratory practices as a criterion for selecting data: the case of bisphenol A. Environ Health Perspect. 2009 Mar;117(3):309-15. doi: 10.1289/ehp.0800173

¹⁴ Dr. Kristi Pullen Fedinick, NRDC. Draft Considerations for the Development of the Strategic Plan for Developing and Implementing Alternative Test Methods and Strategies to Reduce, Refine, or Replace Vertebrate Animal Testing for Chemical Substances or Mixtures. EPA Docket EPA-HQ-OPPT-2017-0559. January 10, 2018

⁹ National Research Council. 2014. Review of EPA's Integrated Risk Information System (IRIS) Process. Washington, DC: The National Academies Press. https://doi.org/10.17226/18764.

¹⁰ Christopher J. Borgert, Richard A. Becker, Betsy D. Carlton, Mark Hanson, Patricia L. Kwiatkowski, Mary Sue Marty, Lynn S. McCarty, Terry F. Quill, Keith Solomon, Glen Van Der Kraak, Raphael J. Witorsch, Kun Don Yi; Does GLP enhance the quality of toxicological evidence for regulatory decisions?, Toxicological Sciences, Volume 151, Issue 2, 1 June 2016, Pages 206–213, https://doi.org/10.1093/toxsci/kfw056

Diminished concordance with animal systems/high false negative rate - When comparing guideline and guideline-like studies to an ATM developed for screening under the Endocrine Disruptor Screening Program, the ToxCast[™]-derived "ER Model" missed nearly 30 percent (15/55¹⁵) of the *in vivo* estrogenic reference chemicals¹⁶ from guideline-like studies and 3 percent (1 out of 30 chemicals) of estrogenic reference chemicals from guideline studies¹⁷. The lack of sensitivity (high false negative rate) of the "ER Model" and similar ATMs for *in vivo* studies is problematic and leads to decreased confidence in the ability of the model to reliably identify chemicals that could disrupt biological processes in whole animal (including human) systems.

Overly narrow exposure estimates in high-throughput models – The current models used by the Agency to generate high-throughput population-level exposure estimates are severely limited in their capacity to generate values for vulnerable populations. The reliance on National Health and Nutritional Examination Survey (CDC-NHANES) data for the generation of model estimates prevents the ExpoCast program from accurately identifying exposures in vulnerable populations including children under the age of 6, highly exposed populations (e.g., workers) and vulnerable populations (e.g., pregnant women). These large uncertainties limit their use as gap-filling data.

For the potential benefits of ATMs to be realized, EPA must be encouraged by the NAS to develop and incorporate use of such methods over realistic timeframes, with a commitment to ensuring methods' effectiveness, and without a rush to eliminate use of proven existing methods for assessing toxicity and exposure.

In conclusion, the protection of EPA's scientific independence and integrity is of great concern to regulators, manufacturers, businesses, scientists, academics, health professionals, and the public. We appreciate the work of the NAS to review the progress of the IRIS Program, and we hope that its final report will provide support for the continuation of an independent chemical assessment program committed to using the best scientific methods for ensuring protection for public health and the environment.

Thank you for your consideration of these comments.

Respectfully,

Jennifer Sass

Jennifer Sass, Ph.D.

¹⁵ For this discussion, false negatives include chemicals that were incorrectly identified as not having estrogenic activity and those with "inconclusive" results.

¹⁶ Estrogenic *in vivo* reference chemicals missed by the "ER Model" include methylparaben, triclosan, reserpine, permethrin, octamethylcyclotetrasiloxane, and gibberellic acid. Inconclusive chemicals cannot be specifically listed due to coded identities in footnote 8.

¹⁷ Browne, P., Judson, R. S., Casey, W., Kleinstreuer, N., & Thomas, R. S. (2015). Screening Chemicals for Estrogen Receptor Bioactivity Using a Computational Model. Environmental Science & Technology, 150612115349008. http://doi.org/10.1021/acs.est.5b02641

Senior Scientist, Natural Resources Defense Council, and Professorial Lecturer, George Washington University, Milken Institute School of Public Health Department of Environmental and Occupational Health Tel: 202.289.2362; E: jsass@nrdc.org

Academic titles and affiliations are provided for identification purposes only and do not constitute or imply institutional endorsement.

Margaret A. Adgent, MSPH, PhD Research Assistant Professor, Department of Pediatrics Vanderbilt University Medical Center Nashville, TN

Alaska Community Action on Toxics Pamela Miller, Executive Director

Alliance of Nurses for Healthy Environments Katie Huffling, RN, MS, CNM, Executive Director

Frank S. Anastasi, PG Principal, SCA Associates

Laura Anderko PhD RN Robert and Kathleen Scanlon Endowed Chair in Values Based Health Care, and Professor, School of Nursing & Health Studies Georgetown University

David C. Bellinger, PhD, MSc Professor, Harvard Medical School Boston, MA

Chris Borello Concerned Citizens of Lake Township (CCLT) Industrial Excess Landfill (IEL) Superfund Site, Uniontown, Ohio

Robert W. Bowcock Integrated Resource Management, Inc. Claremont, California

Asa Bradman, PhD, MS Associate Adj. Professor of Environmental Health Sciences Center for Environmental Research and Children's Health School of Public Health/UC Berkeley Berkeley, CA

Citizens For A Clean Pompton Lakes

Lisa J. Riggiola Executive Director

Citizens for Safe Water Around Badger - CSWAB.org Laura Olah, Executive Director

Joseph M. Braun, MSPH, PhD RGSS Assistant Professor of Public Health Assistant Professor of Epidemiology Epidemiology Master's Program Director Brown University School of Public Health Providence, RI

Breast Cancer Prevention Partners Janet Nudelman, Director of Program and Policy

Erin Brockovich Foundation Erin Brockovich Claremont, California

Lindsey J. Butler Environmental Health Doctoral Candidate Boston University School of Public Health

California Rural Legal Assistance Foundation Anne Katten, Pesticide and Work Safety Project Director

Courtney Carignan, Ph.D. Assistant Professor, Department of Food Science and Human Nutrition Department of Pharmacology and Toxicology Michigan State University

Center for Biological Diversity Nathan Donley, PhD, Senior Scientist

Center for Environmental Health Ansje Miller, Director of Policy and Partnerships

Center for Health, Environment & Justice A Project of People's Action Institute Stephen Lester, PhD, Science Director

Center for Progressive Reform Matthew Shudtz, Executive Director

Citizens' Environmental Coalition Barbara Warren, RN, MS, Executive Director

Clean and Healthy New York

Kathleen A. Curtis, LPN, Executive Director

Clean Production Action Mark S. Rossi, PhD, Executive Director

Coming Clean Judith Robinson, Executive Director

Commonweal Sharyle Patton, Director Health and Environment Program Bolinas, CA

Cynthia Curl, PhD Assistant Professor Department of Community and Environmental Health Boise State University

Don't Waste Arizona Stephen Brittle, President Phoenix, AZ

Earthjustice Tyler J. Smith, MPH Staff Scientist, New York, NY

Jerome M. Ensminger Agency for Toxic Substances and Disease Control Camp Lejeune Community Assistance Panel (CAP)

Environmental Health Strategy Center/Prevent Harm Patrick MacRoy, Deputy Director

Environmental Justice Health Alliance Richard Moore, National Co-Coordinator Michele Roberts, National Co-Coordinator

Environmental Working Group Ken Cook, President Washington, DC

Brenda Eskenazi, PhD Jennifer and Brian Maxwell Professor of Maternal and Child Health and Epidemiology Director, Center for Environmental Research and Children's Health (CERCH) School of Public Health University of California, Berkeley

Pam Factor-Litvak, PhD

Professor of Epidemiology Associate Dean for Research Resources Mailman School of Public Health Columbia University

Shohreh F. Farzan, PhD Assistant Professor of Preventive Medicine Keck School of Medicine of University of Southern California

Steven G. Gilbert, PhD, DABT INND (Institute of Neurotoxicology & Neurological Disorders) Seattle, WA

Robert M. Gould, MD Associate Adjunct Professor Program on Reproductive Health and the Environment Department of Obstetrics, Gynecology and Reproductive Sciences UCSF School of Medicine Past-President, Physicians for Social Responsibility

Green Science Policy Institute Arlene Blum, PhD, Executive Director Tom Bruton, PhD. Science and Policy Fellow

Alexis Jeannine Handal, PhD MPH Associate Professor, College of Population Health Senior Fellow - Robert Wood Johnson Foundation Center for Health Policy University of New Mexico

Kim Harley, PhD Associate Director for Health Effects, Center for Environmental Research and Children's Health University of California, Berkeley Berkeley, California

Health Care Without Harm and Practice Greenhealth Paul Bogart, Executive Director

Healthy Building Network Tom Lent, Policy Director

Wendy Heiger-Bernays, PhD Clinical Professor of Environmental Health Boston University School of Public Health

International Center for Technology Assessment Jaydee Hanson, Policy Director

Molly Jacobs, MPH University of Massachusetts Lowell Lowell Center for Sustainable Production Lowell, MA

Amy E. Kalkbrenner Associate Professor Zilber School of Public Health University of Wisconsin-Milwaukee

Margaret Karagas Professor, Geisel School of Medicine Dartmouth College

David Kriebel, Sc.D., Professor Lowell Center for Sustainable Production University of Massachusetts Lowell Lowell MA

Philip J. Landrigan, MD, MSc, FAAP Dean for Global Health Professor of Preventive Medicine and Pediatrics Arnhold Institute for Global Health Icahn School of Medicine at Mount Sinai New York, NY

Bruce Lanphear, MD, MPH Professor, Simon Fraser University Vancouver BC, Canada

Learning Disabilities Association of America Maureen Swanson, MPA Director, Healthy Children Project

Victoria Leonard, RN, NP, PhD San Francisco, CA

Jianghong Liu, PhD, FAAN Associate Professor, University of Pennsylvania Schools of Nursing and Medicine Philadelphia, Pennsylvania

Maryland Pesticide Network Ruth Berlin, LCSW-C Executive Director

Merrimack Citizens for Clean Water (NH) Laurene Allen, LICSW, Founder David Michaels, PhD, MPH Professor I Department of Environmental and Occupational Health Milken Institute School of Public Health I The George Washington University

Midwest Environmental Justice Organization Maria Powell, PhD, President Madison, WI

Howard W. Mielke, Ph.D. Department of Pharmacology Tulane University School of Medicine

Mark Miller, MD Assistant Clinical Professor, University of California San Francisco

Gina Muckle Professor, School of Psychology, Université Laval, Canada

Susan K. Murphy, PhD Associate Professor of Obstetrics and Gynecology Chief, Division of Reproductive Sciences Program Director, NICHES Children's Environmental Health and Disease Prevention Research Center Duke University Medical Center Durham, NC

National Hispanic Medical Association Elena Rios, MD, MSPH, FACP President & CEO

NJ Friends of Clearwater Ed Dlugosz, President Red Bank, New Jersey

Northwest Green Chemistry Lauren Heine, Ph.D. Executive Director Spokane, WA

Heather B Patisaul Professor Department of Biological Sciences Keck Center for Behavioral Biology Center for Human Health and the Environment NC State University Raleigh, NC Jerome A. Paulson, MD, FAAP Professor Emeritus of Pediatrics and of Environmental & Occupational Health George Washington University School of Medicine and Health Sciences and Milken Institute School of Public Health

Peaceful Skies Coalition Carol Miller, MPH, President

People Concerned About Chemical Safety Pam Nixon, President Charleston, WV

Janet Perlman, MD, MPH Clinical Professor of Pediatrics University of California, San Francisco, CA

Physicians for Social Responsibility Kathy Attar, MPH Environmental Health Program Manager

Beate Ritz MD, PhD Professor of Epidemiology Center for Occupational and Environmental Health FSPH, University of California Los Angeles

I Leslie Rubin MD Morehouse School of Medicine Southeast Pediatric Environmental Health Specialty Unit, Emory University Atlanta, Georgia

Science and Environmental Health Network Ted Schettler MD, MPH, Science Director

Jennifer Schlezinger, Ph.D. Associate Professor of Environmental Health Boston University School of Public Health Boston, MA

Peter Strauss PM Strauss & Associates San Francisco, CA

Evelyn O. Talbott, DrPH, MPH Professsor, Dept of Epidemiology University of Pittsburgh, Pittsburgh, PA Martha María (Mara) Téllez Rojo, Investigadora Ciencias Médicas F, Centro de Investigación en Nutrición y Salud, Instituto Nacional de Salud Pública, Mexico

The Environmental Health Leadership Foundation Jeanne A Conry MD, PhD President

The Marbledale Road Environmental Coalition, Rachel Zolottev, President Eastchester, NY

Toxics Action Center Shaina Kasper, Vermont and New Hampshire State Director

Tribal Healthy Homes Network Gillian Gawne-Mittelstaedt, MPA, Director

Union of Concerned Scientists Andrew A. Rosenberg, Ph.D. Director, Center for Science and Democracy

Dania Valvi, M.D. M.P.H Ph.D. Research Associate, Department of Environmental Health Harvard T.H. Chan School of Public Health Boston, Massachusetts

Voluntary Cleanup Advisory Board Tim Lopez, President Denver, Colorado

W.A.T.E.R., Wake-up Alaskans to the Toxic Environmental Reality David Berrey, President Fairbanks, Alaska

Robin M. Whyatt, DrPH Professor Emeritus Department of Environmental Health Sciences Mailman School of Public Columbia University

Kimberly Yolton, PhD Professor of Pediatrics Cincinnati Children's Hospital R. Thomas Zoeller, PhD Professor of Biology Director, Laboratory of Molecular & Cellular Biology University of Massachusetts, Amherst